{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:27:21Z","timestamp":1794634041389,"version":"4.9.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pnpbp.2026.111915","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:50:27Z","timestamp":1788619827000},"page":"111915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Potential role of 5-HT7 receptor antagonists in the treatment of depression: Pharmacological and bioengineering perspectives"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1081-9143","authenticated-orcid":false,"given":"Arghya Kusum","family":"Dhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2509-2372","authenticated-orcid":false,"given":"Ruchi","family":"Keswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-5334","authenticated-orcid":false,"given":"Kuttiappan","family":"Anitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6319-675X","authenticated-orcid":false,"given":"Gauri","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6576-4753","authenticated-orcid":false,"given":"Aryaa","family":"Nigade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3462","authenticated-orcid":false,"given":"Shvetank","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0010","article-title":"Role of asenapine as an augmenter for treatment-resistant schizophrenia","volume":"1","author":"Al Jumaili","year":"2022","journal-title":"Psychiatry Res. Case Rep."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111915_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12091994","article-title":"Factors associated with the development of depression and the influence of obesity on depressive disorders: a narrative review","volume":"12","author":"Alberti","year":"2024","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111915_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2022.103311","article-title":"Genetic and epigenetic factors associated with depression: an updated overview","volume":"29","author":"Alshaya","year":"2022","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0030","author":"Amisulpride - an overview"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111915_bb0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/aur.1395","article-title":"Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf\/J mice","volume":"7","author":"Amodeo","year":"2014","journal-title":"Autism Res."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111915_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/JCP.0000000000001889","article-title":"Lack of efficacy of JNJ-18038683 on cognitive impairment in patients with stable bipolar disorder","volume":"44","author":"Arshadi","year":"2024","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0045","series-title":"Handbook of Metabolic Pathways of Xenobiotics","first-page":"1","article-title":"Lurasidone","author":"Azhar","year":"2026"},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111915_bb0050","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J. Med. Chem."},{"issue":"31","key":"10.1016\/j.pnpbp.2026.111915_bb0055","doi-asserted-by":"crossref","first-page":"23422","DOI":"10.1016\/S0021-9258(19)49479-9","article-title":"Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase","volume":"268","author":"Bard","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111915_bb0060","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.drudis.2020.05.001","article-title":"Role of oxidative stress in depression","volume":"25","author":"Bhatt","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111915_bb0065","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2174\/1570159X18666201015155816","article-title":"5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders","volume":"19","author":"Bhatt","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11011-022-01095-1","article-title":"Targeting inflammation: a potential approach for the treatment of depression","volume":"38","author":"Bhatt","year":"2023","journal-title":"Metab. Brain Dis."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0075","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871527321666220329140804","article-title":"Role of brain-gut-microbiota Axis in depression: emerging therapeutic avenues","volume":"22","author":"Bhatt","year":"2023","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/acschemneuro.8b00283","article-title":"Pharmacology and therapeutic potential of the 5-HT7 receptor","volume":"10","author":"Blattner","year":"2019","journal-title":"ACS Chem. Nerosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.107.119404","article-title":"Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents","volume":"321","author":"Bonaventure","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.112.193995","article-title":"Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder","volume":"342","author":"Bonaventure","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01931-0","article-title":"The cell adhesion molecule CD44 acts as a modulator of 5-HT7 receptor functions","volume":"22","author":"Borsdorf","year":"2024","journal-title":"Cell Commun. Signal. CCS"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0100","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2015.11.040","article-title":"Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: multiobjective based design, synthesis, and antidepressant and anxiolytic properties","volume":"108","author":"Canale","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.pnpbp.2026.111915_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26133828","article-title":"Design, sustainable synthesis and biological evaluation of a novel dual \u03b12A\/5-HT7 receptor antagonist with antidepressant-like properties","volume":"26","author":"Canale","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuropharm.2013.01.023","article-title":"Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype","volume":"70","author":"Cates","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1570159X15666170911121027","article-title":"Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the modulation of pain response in the central nervous system","volume":"16","author":"Cortes-Altamirano","year":"2018","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","article-title":"Major depressive disorder: hypothesis, mechanism, prevention and treatment","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/YCO.0b013e3282f32408","article-title":"Major depression and comorbid substance use disorders","volume":"21","author":"Davis","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/cns.12698","article-title":"Asenapine modulates mood-related behaviors and 5-HT 1A\/7 receptors-mediated neurotransmission","volume":"23","author":"Delcourte","year":"2017","journal-title":"CNS Neurosci. Ther."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111915_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115218","article-title":"Serotonergic regulation in Alzheimer\u2019s disease","volume":"26","author":"Dolgacheva","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111915_bb0145","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111915_bb0155","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/02698811231211228","article-title":"The 5-HT7 receptor system as a treatment target for mood and anxiety disorders: a systematic review","volume":"37","author":"Gottlieb","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/ejn.16651","article-title":"Are animal models necessary? Exploring (dis)advantages and alternatives","volume":"61","author":"Guimar\u00e3es","year":"2025","journal-title":"Eur. J. Neurosci."},{"issue":"OCT","key":"10.1016\/j.pnpbp.2026.111915_bb0165","article-title":"Cellular mechanisms of the 5-HT7 receptor-mediated signaling","volume":"8","author":"Guseva","year":"2014","journal-title":"Front. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111915_bb0170","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1124\/jpet.104.081919","article-title":"Differential agonist-mediated internalization of the human 5-hydroxytryptamine 7 receptor isoforms","volume":"313","author":"Guthrie","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0175","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1046\/j.1471-4159.1997.68041372.x","article-title":"Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization","volume":"68","author":"Heidmann","year":"1997","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111915_bb0180","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0028-3908(98)00070-7","article-title":"Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing","volume":"37","author":"Heidmann","year":"1998","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0185","first-page":"244","article-title":"The comorbidity of major depression and anxiety disorders: recognition and Management in Primary Care","volume":"3","author":"Hirschfeld","year":"2001","journal-title":"Primary Care Companion J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nurx.2005.12.007","article-title":"Advances in the treatment of depression","volume":"3","author":"Holtzheimer","year":"2006","journal-title":"NeuroRx"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbr.2013.01.026","article-title":"The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone","volume":"244","author":"Horisawa","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13090","article-title":"Amisulpride as a potential disease-modifying drug in the treatment of tauopathies","author":"Jahreis","year":"2023","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0210","author":"JNJ-18038683 | 5-HT Receptor"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1471-4159.2004.02832.x","article-title":"Enhanced activation of Akt and extracellular-regulated kinase pathways by simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A receptors in PC12 cells","volume":"92","author":"Johnson-Farley","year":"2005","journal-title":"J. Neurochem."},{"issue":"11 Suppl 2","key":"10.1016\/j.pnpbp.2026.111915_bb0220","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.amjmed.2008.09.008","article-title":"The comorbidity of diabetes mellitus and depression","volume":"121","author":"Katon","year":"2008","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0225","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mp.2016.120","article-title":"HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition","volume":"22","author":"Keller","year":"2017","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0230","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/jm980519u","article-title":"Tetrahydrobenzindoles: selective antagonists of the 5-HT7 receptor","volume":"42","author":"Kikuchi","year":"1999","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111915_bb0235","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1021\/jm0104264","article-title":"2a-[4-(Tetrahydropyridoindol-2-yl)butyl]tetrahydrobenzindole derivatives: new selective antagonists of the 5-hydroxytryptamine7 receptor","volume":"45","author":"Kikuchi","year":"2002","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0960-894X(02)00842-9","article-title":"New tetrahydrobenzindoles as potent and selective 5-HT7 antagonists with increased in vitro metabolic stability","volume":"13","author":"Kikuchi","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2026.111915_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2008.09.014","article-title":"A review of panic and suicide in bipolar disorder: does comorbidity increase risk?","volume":"115","author":"Kilbane","year":"2009","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0250","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/mol.108.052084","article-title":"Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-risperidone, and other inactivating antagonists","volume":"75","author":"Knight","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111915_bb0255","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1523\/JNEUROSCI.2765-11.2012","article-title":"5-HT7R\/G12 Signaling regulates neuronal morphology and function in an age-dependent manner","volume":"32","author":"Kobe","year":"2012","journal-title":"J. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2026.111915_bb0260","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(02)02003-4","article-title":"DR4004, a putative 5-HT7 receptor antagonist, also has functional activity at the dopamine D2 receptor","volume":"449","author":"Kogan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108779","article-title":"5-HT(7) receptors enhance inhibitory synaptic input to principal neurons in the mouse basal amygdala","volume":"198","author":"Kusek","year":"2021","journal-title":"Neuropharmacology"},{"issue":"34","key":"10.1016\/j.pnpbp.2026.111915_bb0270","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1523\/JNEUROSCI.1790-05.2005","article-title":"5-HT7 receptor is coupled to g\u03b1 subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology","volume":"25","author":"Kvachnina","year":"2005","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2010.08.013","article-title":"Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders","volume":"129","author":"Leopoldo","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2023.1124112","article-title":"Latest updates on the serotonergic system in depression and anxiety","volume":"15","author":"Lin","year":"2023","journal-title":"Front. Synaptic Neurosci."},{"issue":"21","key":"10.1016\/j.pnpbp.2026.111915_bb0285","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0024-3205(01)01318-2","article-title":"Expression patterns of 5-HT7 receptor isoforms in the rat digestive tract","volume":"69","author":"Liu","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jad.2021.09.109","article-title":"A randomized, double-blind, placebo-controlled proof-of-concept trial to evaluate the efficacy and safety of non-racemic amisulpride (SEP-4199) for the treatment of bipolar I depression","volume":"296","author":"Loebel","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"26","key":"10.1016\/j.pnpbp.2026.111915_bb0295","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1021\/jm030841r","article-title":"Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives","volume":"46","author":"L\u00f3pez-Rodr\u00edguez","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/1568015043356931","article-title":"Serotonin 5-HT 7 receptor antagonists","volume":"4","author":"L\u00f3pez-Rodr\u00edguez","year":"2004","journal-title":"Curr. Med. Chem.-Central Nervous System Agents"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111915_bb0305","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/jm991151j","article-title":"A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970)","volume":"43","author":"Lovell","year":"2000","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0310","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11920-023-01423-x","article-title":"Suicide in global mental health","volume":"25","author":"Lovero","year":"2023","journal-title":"Curr. Psychiatry Rep."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111915_bb0315","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/wps.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111915_bb0320","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/jnc.13981","article-title":"5-HT7 receptor shapes spinogenesis in cortical and striatal neurons: an editorial highlight for \u201cserotonin 5-HT7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons\u201d. In","volume":"141","author":"Marin","year":"2017","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0325","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjp.0705576","article-title":"Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species","volume":"141","author":"Mart\u00edn-Cora","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111915_bb0330","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/jm8014553","article-title":"Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7\/5-HT1A receptor selectivity","volume":"52","author":"Medina","year":"2009","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111915_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11101298","article-title":"HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation","volume":"11","author":"Mikulska","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110775","article-title":"Association between inflammatory cytokines and symptoms of major depressive disorder in adults","volume":"14","author":"Min","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111915_bb0345","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2174\/138945009789735129","article-title":"Therapeutic potential of 5-HT7 receptors in mood disorders","volume":"10","author":"Mnie-Filali","year":"2009","journal-title":"Curr. Drug Targets"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0350","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/npp.2011.13","article-title":"Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy","volume":"36","author":"Mnie-Filali","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"19","key":"10.1016\/j.pnpbp.2026.111915_bb0355","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1021\/acs.jmedchem.7b01898","article-title":"Structure-activity relationships and therapeutic potentials of 5-HT(7) receptor ligands: an update","volume":"61","author":"Modica","year":"2018","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0360","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/153331750201700607","article-title":"Depression and Alzheimer\u2019s disease: symptom or comorbidity?","volume":"17","author":"Moretti","year":"2002","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0365","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ame2.12487","article-title":"Animal models in neuroscience with alternative approaches: evolutionary, biomedical, and ethical perspectives","volume":"7","author":"Neziri","year":"2024","journal-title":"An. Models Exp. Med."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0370","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-015-0236-0","article-title":"Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders: rationale and Progress to date","volume":"29","author":"Nikiforuk","year":"2015","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0375","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archpsyc.64.2.201","article-title":"Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography","volume":"64","author":"Oquendo","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111915_bb0380","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1038\/s41380-025-03116-8","article-title":"Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2\/D3 antagonism, D2\/D3 partial agonism and placebo","volume":"30","author":"Osugo","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0385","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/bkcs.70172","article-title":"Serotonin 5-HT7 receptor signaling in neuropsychiatric disorders","volume":"47","author":"Park","year":"2026","journal-title":"Bull. Korean Chem. Soc."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0390","series-title":"Anxiolytic-like activity of PZ-1433, a novel ARYLSULFONAMIDE derivative of Aryloxy(Propyl)Piperidine, in Rodents","author":"Partyka","year":"2018"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0395","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbr.2018.10.004","article-title":"Novel antagonists of 5-HT 6 and\/or 5-HT 7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats","volume":"359","author":"Partyka","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0400","series-title":"SB-258741: A 5-HT 7 Receptor Antagonist of Potential Clinical Interest","author":"Pouzet","year":"2002"},{"issue":"16","key":"10.1016\/j.pnpbp.2026.111915_bb0405","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.230334","article-title":"Serotonin receptor oligomerization regulates cAMP-based signaling","volume":"132","author":"Prasad","year":"2019","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0410","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.comppsych.2010.09.006","article-title":"Comorbid major depression in obsessive-compulsive disorder patients","volume":"52","author":"Quarantini","year":"2011","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0415","article-title":"Role of 5-HT(7) receptors in the immune system in health and disease","volume":"26","author":"Quintero-Villegas","year":"2019","journal-title":"Mol. Med. (Cambridge, Mass.)"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0420","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-022-00497-2","article-title":"Central nervous system effects of 5-HT7 receptors: a potential target for neurodegenerative diseases","volume":"28","author":"Quintero-Villegas","year":"2022","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111915_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11121633","article-title":"Biological, psychological, and social determinants of depression: a review of recent literature","volume":"11","author":"Remes","year":"2021","journal-title":"Brain Sci."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111915_bb0430","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/jnr.25055","article-title":"Serotonin 5-HT7 receptor overexpression in the raphe nuclei area produces antidepressive effect and affects brain serotonin system in male mice","volume":"100","author":"Rodnyy","year":"2022","journal-title":"J. Neurosci. Res."},{"issue":"18","key":"10.1016\/j.pnpbp.2026.111915_bb0435","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1073\/pnas.90.18.8547","article-title":"Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation","volume":"90","author":"Ruat","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0440","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fnbeh.2014.00391","article-title":"5-HT7 receptor activation promotes an increase in TrkB receptor expression and phosphorylation","volume":"8","author":"Samarajeewa","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0445","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0450","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2010.01.022","article-title":"The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior","volume":"209","author":"Sarkisyan","year":"2010","journal-title":"Behav. Brain Res."},{"issue":"JUL","key":"10.1016\/j.pnpbp.2026.111915_bb0455","article-title":"Genetics factors in major depression disease","volume":"9","author":"Shadrina","year":"2018","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111915_bb0460","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0465","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0470","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1124\/mol.106.024612","article-title":"Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor","volume":"70","author":"Smith","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0475","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/mol.110.069278","article-title":"Risperidone-induced inactivation and clozapine-induced reactivation of rat cortical astrocyte 5-hydroxytryptamine\u2087 receptors: evidence for in situ G protein-coupled receptor homodimer protomer cross-talk","volume":"79","author":"Smith","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111915_bb0480","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111915_bb0485","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.bjp.0701946","article-title":"Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719","volume":"124","author":"Thomas","year":"1998","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0490","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.bjp.0703318","article-title":"[3H]-SB-269970 \u2013 a selective antagonist radioligand for 5-HT7 receptors","volume":"130","author":"Thomas","year":"2000","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0495","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.bjp.0705290","article-title":"SB-656104-a, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats","volume":"139","author":"Thomas","year":"2003","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111915_bb0500","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.156","article-title":"The molecular pathophysiology of depression and the new therapeutics","volume":"3","author":"Tian","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0505","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fnins.2018.00499","article-title":"Brain kynurenine and BH4 pathways: relevance to the pathophysiology and treatment of inflammation-driven depressive symptoms","volume":"12","author":"Vancassel","year":"2018","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111915_bb0510","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40261-017-0592-2","article-title":"A review of Asenapine in the treatment of bipolar disorder","volume":"38","author":"Vieta","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1178494","article-title":"Advances in the knowledge and therapeutics of schizophrenia, major depression disorder, and bipolar disorder from human brain organoid research","volume":"14","author":"Villanueva","year":"2023","journal-title":"Front. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111915_bb0520","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/jm070279v","article-title":"(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists","volume":"51","author":"Volk","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pnpbp.2026.111915_bb0525","article-title":"Neurotrophic basis to the pathogenesis of depression and phytotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"7695","key":"10.1016\/j.pnpbp.2026.111915_bb0530","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature25758","article-title":"Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone","volume":"555","author":"Wang","year":"2018","journal-title":"Nature"},{"issue":"S1","key":"10.1016\/j.pnpbp.2026.111915_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(13)76173-X","article-title":"1053 \u2013 in vitro receptor-binding profile of lurasidone and other commonly-used antipsychotics","volume":"28","author":"Werner","year":"2013","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0540","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2014.10.015","article-title":"Involvement of 5-HT7 receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents","volume":"89","author":"Westrich","year":"2015","journal-title":"Neuropharmacology"},{"issue":"16","key":"10.1016\/j.pnpbp.2026.111915_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27165091","article-title":"Pathophysiology of depression: stingless bee honey promising as an antidepressant","volume":"27","author":"Zakaria","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.pnpbp.2026.111915_bb0550","first-page":"378","article-title":"Emerging brain organoids: 3D models to decipher, identify and revolutionize brain","volume":"47","author":"Zhao","year":"2025","journal-title":"Bioact. Mater."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111915_bb0555","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1523\/JNEUROSCI.1685-18.2018","article-title":"Activation of 5-HT1A receptors promotes retinal ganglion cell function by inhibiting the cAMP-PKA pathway to modulate presynaptic GABA release in chronic Glaucoma","volume":"39","author":"Zhou","year":"2019","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111915_bb0560","first-page":"398","article-title":"Effect of amisulpride on the expression of serotonin receptors, neurotrophic factor BDNF and its receptors in mice with overexpression of the aggregation-prone [R406W] mutant tau protein","volume":"28","author":"\u041a\u043e\u043d\u0434\u0430\u0443\u0440\u043e\u0432\u0430","year":"2024","journal-title":"Vavilovskii Zhurnal Genetiki i Selektsii"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:37:43Z","timestamp":1790714263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626003131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":111,"alternative-id":["S0278584626003131"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111915","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of 5-HT7 receptor antagonists in the treatment of depression: Pharmacological and bioengineering perspectives","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111915"}}